Patients and Methods
Abbreviations and Acronyms:EHR (electronic health record), EU (European Union), FDA (US Food and Drug Administration), MCPFS (Mayo Clinic Pharmaceutical Formulary Subcommittee), SCM (supply chain management)
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- National health care spending in 2019: steady growth for the fourth consecutive year.Health Aff (Millwood). 2021; 40: 14-24
- Biosimilars.https://www.healthaffairs.org/do/10.1377/hpb20131010.6409/full/Date accessed: November 3, 2021
- National trends in prescription drug expenditures and projections for 2021.Am J Health Syst Pharm. 2021; 78: 1294-1308
- Biosimilar cost savings in the United States: initial experience and future potential.Rand Health Q. 2018; 7: 3
- Considerations for adding biosimilars to formulary.Pharm Purch Prod. 2019; 16: 14-19
- Considerations in demonstrating interchangeability with a reference product: Guidance for industry.US Food & Drug Administration, May 2019 (Docket No. FDA-2017-D-0154)
- Can biosimilars help achieve the goals of US health care reform?.Cancer Manag Res. 2017; 9: 197-205
- Category Management In Purchasing : A Strategic Approach to Maximize Business Profitability.Kogan Page, 2009
- Pharmacist’s perspectives on biosimilars in oncology.(Accessed 2021)
- Recommendations on operationalizing the safe and efficient use of biosimilars in the clinical setting. NCCN Pharmacy Directors Forum White Papers.National Comprehensive Cancer Network. 2021;
- Biosimilars.https://www.fda.gov/drugs/therapeutic-biologics-applications-bla/biosimilarsDate accessed: November 4, 2021
- The clinical implications of nocebo effects for biosimilar therapy.Front Pharmacol. 2019; 10: 1372
- Lessons from international experience with biosimilar implementation: an application of the diffusion of innovations model.Healthc Policy. 2020; 15: 16-27
- Longer-term durability of using default options in the electronic health record to increase generic prescribing rates.J Gen Intern Med. 2019; 34: 349-350
- Home dialysis in the coronavirus disease 2019 era.Adv Chronic Kidney Dis. 2020; 27: 442-446
- Clinical experience with Zarzio® in Europe: what have we learned?.Support Care Cancer. 2013; 21: 2925-2932
- Pharmacoeconomics of biosimilars: what is there to gain from them?.Curr Rheumatol Rep. 2016; 18: 50
Troein P, Newton M, Scott K, Mulligan C. White Paper: The impact of biosimilar competition in Europe. IQVIA; January 15, 2021.
- Diffusion of innovations in service organizations: systematic review and recommendations.Milbank Q. 2004; 82: 581-629
- Implementing shared decision making in the NHS.BMJ. 2010; 341: c5146
For editorial comment, see page 1044
Data Previously Presented: These data presented in part at the Hematology/Oncology Pharmacy Association Annual Conference on April 13 to 17, 2021.